HUMAN ERYTHROID-POTENTIATING ACTIVITY

人红细胞增强活性

基本信息

  • 批准号:
    3087368
  • 负责人:
  • 金额:
    $ 6.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1987
  • 资助国家:
    美国
  • 起止时间:
    1987-08-01 至 1991-07-31
  • 项目状态:
    已结题

项目摘要

Hematopoiesis is tightly regulated by a series of hormonal factors that stimulate the proliferation and differentiation of progenitor cells, as well as modulate the functional activity of mature effector cells. Human erythroid-potentiating activity (EPA) is a recently purified and molecularly cloned growth factor which stimulates the growth of erythroid precursors. The precise physiological role of EPA in the regulation of hematopoiesis is unknown. The proposed studies are designed to investigate the mechanisms of action of EPA on normal and neoplastic cells through characterization at the molecular level of the interaction of EPA with its receptor protein. Target cells bearing receptors for EPA as determined by binding of labeled 125I-EPA will be used as a source for purifying the EPA receptor and generating receptor antisera. Molecular clones encoding the EPA receptor will be obtained and used to determine the structure and sequence of the receptor protein and to examine its genomic organization in DNA. The cDNA clones will then be used to study the regulation and expression of the EPA receptor in normal and neoplastic cells. I propose to comprehensively analyze the EPA receptor on normal human peripheral blood and bone marrow cells, various human cell lines, and fresh neoplastic cells. Receptor numbers, binding affinity, and molecular properties of the receptor protein will be studied. Thus, significant differences may be seen in the quantitative or qualitative characteristics of the EPA receptor protein in normal and neoplastic cells which are important in the maintenance of the normal and transformed malignant state. Of particular interest is the possibility of tumor promoting activities or translocations or amplifications of the EPA receptor gene in specific neoplasias, in view of the association of some receptor proteins with oncogenes. Overall, these studies should yield new and important information on the in vivo regulation by EPA of hematopoiesis and its role in the pathophysiology of various disease states. Information gained from these studies should contribute to our basic understanding of the interactions of hematopoietic growth factors and their target cells. On a larger scale, this information should expand our current fundamental knowledge of hematopoietic cell growth and the interaction of growth factors and their receptors in normal and malignant states.
造血受到一系列激素因素的严格调控

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Belinda Rene Avalos其他文献

Belinda Rene Avalos的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Belinda Rene Avalos', 18)}}的其他基金

G-CSF Receptor and Ubiquitination
G-CSF 受体和泛素化
  • 批准号:
    6984691
  • 财政年份:
    2005
  • 资助金额:
    $ 6.95万
  • 项目类别:
G-CSF Receptor and Ubiquitination
G-CSF 受体和泛素化
  • 批准号:
    7140531
  • 财政年份:
    2005
  • 资助金额:
    $ 6.95万
  • 项目类别:
LOSS OF NEGATIVE SIGNALING BY THE G-CSFR IN AML
AML 中 G-CSFR 负信号丢失
  • 批准号:
    6514159
  • 财政年份:
    1999
  • 资助金额:
    $ 6.95万
  • 项目类别:
LOSS OF NEGATIVE SIGNALING BY THE G-CSFR IN AML
AML 中 G-CSFR 负信号丢失
  • 批准号:
    6174121
  • 财政年份:
    1999
  • 资助金额:
    $ 6.95万
  • 项目类别:
LOSS OF NEGATIVE SIGNALING BY THE G-CSFR IN AML
AML 中 G-CSFR 负信号丢失
  • 批准号:
    6377439
  • 财政年份:
    1999
  • 资助金额:
    $ 6.95万
  • 项目类别:
LOSS OF NEGATIVE SIGNALING BY THE GCSFR IN AML
AML 中 GCSFR 负信号丢失
  • 批准号:
    2899455
  • 财政年份:
    1999
  • 资助金额:
    $ 6.95万
  • 项目类别:
G-CSFR MUTATIONS--A NOVEL MECHANISM OF LEUKEMOGENESIS
G-CSFR突变——白血病发生的新机制
  • 批准号:
    2382809
  • 财政年份:
    1997
  • 资助金额:
    $ 6.95万
  • 项目类别:
G-CSFR MUTATIONS--A NOVEL MECHANISM OF LEUKEMOGENESIS
G-CSFR突变——白血病发生的新机制
  • 批准号:
    2748953
  • 财政年份:
    1997
  • 资助金额:
    $ 6.95万
  • 项目类别:
HUMAN ERYTHROID-POTENTIATING ACTIVITY
人红细胞增强活性
  • 批准号:
    3087369
  • 财政年份:
    1987
  • 资助金额:
    $ 6.95万
  • 项目类别:
HUMAN ERYTHROID-POTENTIATING ACTIVITY
人红细胞增强活性
  • 批准号:
    3087366
  • 财政年份:
    1987
  • 资助金额:
    $ 6.95万
  • 项目类别:

相似海外基金

Study on the mechanism of prolonged half-life of blood IgY by unique antibody receptor and its application to immune enhancement in birds
独特抗体受体延长血液IgY半衰期的机制研究及其在禽类免疫增强中的应用
  • 批准号:
    23H02361
  • 财政年份:
    2023
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
  • 批准号:
    nhmrc : GNT1124162
  • 财政年份:
    2017
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Early Career Fellowships
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
  • 批准号:
    nhmrc : 1124162
  • 财政年份:
    2017
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Early Career Fellowships
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
  • 批准号:
    9300976
  • 财政年份:
    2015
  • 资助金额:
    $ 6.95万
  • 项目类别:
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
  • 批准号:
    9920805
  • 财政年份:
    2015
  • 资助金额:
    $ 6.95万
  • 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
  • 批准号:
    8900121
  • 财政年份:
    2012
  • 资助金额:
    $ 6.95万
  • 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
  • 批准号:
    8225814
  • 财政年份:
    2012
  • 资助金额:
    $ 6.95万
  • 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
  • 批准号:
    8699511
  • 财政年份:
    2012
  • 资助金额:
    $ 6.95万
  • 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
  • 批准号:
    8525355
  • 财政年份:
    2012
  • 资助金额:
    $ 6.95万
  • 项目类别:
Small Grants for Exploratory Research: Separation of Cells and Biological Macromolecules by Antibody Receptor Coated Magnetic Vesicles and Ferritin Conjugates
探索性研究小额资助:通过抗体受体包被的磁囊和铁蛋白缀合物分离细胞和生物大分子
  • 批准号:
    9115537
  • 财政年份:
    1991
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了